- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02863172
Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes
Objectives:
- To examine the variations in clinical features, survival outcomes, family history, and health behavior among proband patients who are known or suspected to have a hereditary colorectal cancer syndrome
- To compare the clinical features, survival outcomes, and health behavior of the proband vs. his/her family members who may or may not be affected by the hereditary colorectal cancer syndrome
- To explore for correlations between germline genetic variations in both the probands and family members with observed variations in the overall disease phenotype across probands and kindreds, within a given syndrome. Disease phenotype is defined to include: (1) clinicopathologic features including patient demographics and oncologic outcomes; (2) clinical manifestations of disease including the timing, spectrum and severity of CRC and extracolonic cancers. Genetic variations may include the specific codon mutated, the type of mutation and sequence alteration (e.g. nonsense, missense etc), chromosomal/gene copy number changes, and gene polymorphisms.
- To explore for correlations between germline genetic variations in both the probands and family members with observed variations in somatic CRC tumor biology, including tumor pathology and other tumor molecular markers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants:
Questionnaires:
If participant agrees to take part in this study, participant will fill out a some questionnaires about participant's work, family history, medical history, and health habits. If participant has already answered these questionnaires when participant was registered as a patient at MD Anderson, the study staff will give participant a copy and review participant's answers with participant for any updates or if participant has any questions. It should take about 20 minutes to complete the questionnaires.
Participant will also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. This questionnaire should take about 10 minutes to complete.
Participant may be given the questionnaires electronically on REDcap (a secure, web-based application used to collect data for research studies that participant can access from participant's phone, tablet, or computer), over the phone (either with a member of the study staff asking questions or by using an electronic response system called IVR), at home through the mail, or in person by a member of the research staff at participant's MD Anderson visit. If mailed, a postage-paid return envelope will be provided for the return of the questionnaire.
Blood or Saliva Sample:
Blood (about 2-3 tablespoons) will be drawn. If possible, the blood will be drawn during an already scheduled blood draw to avoid additional needle sticks.
If participant is unwilling or unable to give a blood sample, participant may give a saliva sample instead. If participant is at MD Anderson, a saliva kit will be given to participant. If participant is not at MD Anderson, the kit will be mailed to participant with instructions for collecting the saliva sample and a prepaid envelope will be included to return the sample to the study staff.
The blood or saliva sample will be sent to the research laboratory of the study chairs at MD Anderson for testing.
Residual Tissue Collection:
If participant has tissue from procedures performed at MD Anderson, this tissue may be requested from participant's previous procedures for testing. If participant has had procedures done at another institution, participant may be asked to sign a waiver to allow the tissue from the outside institution to be sent to MD Anderson for testing.
Follow-Up Questionnaires:
Participant will also fill out a follow-up questionnaire at least 1 time in 5 years to update participant's medical, cancer, and family history. Each questionnaire will take approximately 20 minutes to complete.
Withdrawing from the Study:
Participant may withdraw from participation in this study at any time. If participant decides participant wants to stop taking part in this study, data collected about participant and data taken from the blood or saliva samples participant has provided up to the time participant withdraws will remain in study database and will be used for the purposes of the study.
Length of Study:
Participant's active participation on this study will be over after the blood, tissue, and/or saliva samples have been collected and participant has completed all of the questionnaires.
This is an investigational study.
Up to 2,000 patients and/or family members will take part in this study. All will be enrolled at MD Anderson.
Family Members:
Questionnaire:
Participant will complete a health questionnaire, which will collect information about participant's personal medical history, demographics (age, race, sex, and so on), and questions about participant's alcohol and tobacco use. This questionnaire should take about 20 minutes to complete.
Participant may be given the questionnaires electronically on REDcap (a secure, web-based application used to collect data for research studies that participant can access from participant's phone, tablet, or computer), over the phone (either with a member of the study staff asking questions or by using an electronic response system called IVR), at home through the mail, or in person by a member of the research staff at participant's family member's MD Anderson visit.
If mailed, a postage-paid return envelope will be provided for the return of the questionnaire.
Blood or Saliva Sample:
If participant agrees to take part in this study and participant is able to come to MD Anderson, blood (about 2-3 tablespoons) will be drawn.
If participant is unwilling or unable to give a blood sample, participant may give a saliva sample instead. If participant is at MD Anderson, a saliva kit will be given to participant. If participant is not at MD Anderson, the kit will be mailed to participant with instructions for collecting the saliva sample and a prepaid envelope will be included to return the sample to the study staff.
The blood or saliva sample will be sent to the research laboratory of the study chairs at MD Anderson for testing.
Outside Tissue Collection:
If participant has had a procedure done at a hospital, surgical center, or doctor's office outside of MD Anderson, participant may optionally be asked to sign a waiver to allow tissue stored at the outside hospital, surgical center, or doctor's office to be sent to researchers at MD Anderson.
Follow-Up Questionnaires:
Participant will also fill out a follow-up questionnaire at least 1 time in 5 years to update participant's medical, cancer, and family history. Each questionnaire will take approximately 20 minutes to complete.
Withdrawing from the Study:
Participant may withdraw from participation in this study at any time. If participant decides participant wants to stop taking part in this study, data collected about participant and data taken from the blood or saliva samples participant has provided up to the time participant withdraws will remain in study database and will be used for the purposes of the study.
Length of Study Participant's active participation on this study will be over after the blood, outside tissue and/or saliva samples have been collected and participant has completed all of the questionnaires.
This is an investigational study. Up to 2,000 patients and/or family members will take part in this study. All will be enrolled at MD Anderson.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Yi-Qian N. You, MD
- Phone Number: 713-792-6940
- Email: YNYou@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77330
- Recruiting
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Probands who meet the following criteria will be eligible:
- Patient must have or is suspected to have a hereditary CRC syndrome
- Patient must be at least 18 years of age at the time of study registration.
- Patient must have sufficient command of the English language and mental capacity to provide consent
Family members who meet the following criteria will be eligible:
- First- or second-degree relative of a registered MDACC patient who has met eligibility criteria for a Proband as defined above.
- Family member must be at least 18 years of age at the time of study registration.
- Family member must have sufficient command of the English language and mental capacity to provide consent
Exclusion Criteria:
N/A
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Consenting Proband Group
Questionnaires completed at baseline.
Blood sample taken at baseline.
Follow-up questionnaire completed at least 1 time in 5 years.
|
Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history. Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history.
Other Names:
About 2-3 tablespoons blood drawn.
Participants may give a saliva sample instead.
|
|
Family Members (MDA Registered Patients) Group
Health questionnaire completed at baseline.
Blood sample taken at baseline.
Follow-up questionnaire completed at least 1 time in 5 years.
|
Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history. Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history.
Other Names:
About 2-3 tablespoons blood drawn.
Participants may give a saliva sample instead.
|
|
Family Members (Not MDA Registered Patients) Group
Health questionnaire completed at baseline.
Blood sample taken at baseline.
Follow-up questionnaire completed at least 1 time in 5 years.
|
Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history. Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history.
Other Names:
About 2-3 tablespoons blood drawn.
Participants may give a saliva sample instead.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variations in Clinical Features Compared Between Proband Group and Family Member Group
Time Frame: 5 years
|
Comparison made using 1-way ANOVA or Chi-squared tests.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variations in the Overall Disease Phenotype Between Proband Group and Family Member Group
Time Frame: 5 years
|
Disease phenotype defined to include: (1) clinicopathologic features including patient demographics and oncologic outcomes; (2) clinical manifestations of disease including the timing, spectrum and severity of CRC and extracolonic cancers.
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yi-Qian N. You, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Intestinal Diseases
- Disease
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colonic Diseases
- Syndrome
- Colorectal Neoplasms
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Surveys and Questionnaires
Other Study ID Numbers
- PA11-0567
- 2015-00051016-Y1 (Other Grant/Funding Number: MD Anderson)
- 2016-00051406 (Other Grant/Funding Number: Eduardo Vilar-Sanchez, MD, PhD, Germline Precision Prevention in Adolescents)
- NCI-2020-07461 (Other Identifier: Clinical Trials Reporting Program (CTRP))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Colorectal Cancer Syndrome
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Hereditary Neoplastic Syndrome | BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome | BRCA2-Related Hereditary Breast and Ovarian Cancer SyndromeUnited States
-
University of Vermont Medical CenterEnrolling by invitationLynch Syndrome | Hereditary Cancer Syndromes | BRCA1 Hereditary Breast and Ovarian Cancer SyndromeUnited States
-
State Scientific Centre of Coloproctology, Russian...The Loginov MCSC MHD; Pirogov National Medical and Surgical Center; Moscow City... and other collaboratorsRecruitingColorectal Cancer | Lynch Syndrome | Hereditary Colorectal Cancer | MSIRussian Federation
-
Josh PetersonNational Cancer Institute (NCI); National Human Genome Research Institute (NHGRI)RecruitingHereditary Colorectal Cancer | Hereditary Breast Cancer | Hereditary Pancreatic Cancer | Conditions or Focus of StudyUnited States
-
Izmir Ataturk Training and Research HospitalNot yet recruitingLynch Syndrome | Colo-rectal Cancer | Hereditary Diseases
-
University of Medicine and Pharmacy at Ho Chi Minh...Gene SolutionsNot yet recruitingLynch Syndrome | Colorectal Cancer (CRC)Vietnam
-
Wageningen UniversityDutch Cancer Society; Wereld Kanker Onderzoek Fonds; Funding: Biobanking and...RecruitingNeoplasms | Colorectal Neoplasms | Lynch Syndrome | Hereditary Nonpolyposis Colorectal CancerNetherlands
-
Sun Yat-sen UniversityNot yet recruitingLynch Syndrome | Colorectal Cancer Screening
-
M.D. Anderson Cancer CenterCompletedLynch Syndrome | Hereditary Nonpolyposis Colorectal CancerUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale; IRCCS Ospedale San...Active, not recruitingColorectal Cancer | Turcot Syndrome | Desmoid Tumor | Duodenal Adenoma | Familial Adenomatous Polyposis (FAP) | Desmoid-Type Fibromatosis | Hereditary Colorectal Cancer Syndrome | Gardner Syndrome | Attenuated Familial Adenomatous Polyposis (AFAP) | MUTYH-Associated Polyposis (MAP) | Non-APC/MUTYH Associated... and other conditionsItaly
Clinical Trials on Questionnaires
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
University Hospital, ToulouseNot yet recruiting
-
Direction Centrale du Service de Santé des ArméesCompleted
-
Sun Yat-sen UniversityNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisRecruitingIntensive Care Unit Syndrome | Pediatric Post-intensive Care SyndromeFrance
-
Nova Scotia Health AuthorityNot yet recruitingStroke | Amputation | Spinal Cord Injury | Caregivers | Wheelchair Users | Wheelchair Service ProvidersCanada
-
M.D. Anderson Cancer CenterCompletedAdvanced Cancer | Malignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
The University of Hong KongCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
UNC Lineberger Comprehensive Cancer CenterCompletedBreast Cancer | MetastasisUnited States